Tailored drug tests offer new hope for cystic fibrosis patients with rare mutations
NCT ID NCT04580368
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study aims to find effective treatments for people with cystic fibrosis who have rare gene mutations not approved for current drugs. Researchers will test FDA-approved CFTR modulators on nasal cells in the lab, then confirm the best option in a personalized N-of-1 trial. The study enrolls 50 participants aged 6 and older. The goal is to improve lung function by at least 5%.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CCHMC
RECRUITINGCincinnati, Ohio, 45203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.